We use cookies to make this site work. We'd also like to set optional cookies so we can understand how the site is used and improve it. We will not set optional cookies unless you accept them. You can change your choice at any time from the Cookie settings link in the footer.
Strictly necessary cookies
These cookies are required for the site to work. They store your cookie preferences and keep your session secure. They are exempt from consent under PECR Regulation 6(4) because they are essential to deliver the service you have requested.
Optional cookies
Optional cookies help us understand how the site is used and provide additional features such as analytics, accessibility tools and translation. We will only set them if you accept.
EASi-KIDNEY
The Study of Heart and Kidney Protection with BI 690517 in combination with empagliflozin
Do you have chronic kidney disease and are you interested in research?
Some people with kidney disease develop heart problems or will progress to require long-term dialysis or transplantation. EASi-KIDNEY is an international study investigating a new treatment called BI 690517 in combination with the well tested treatment empagliflozin to slow the progression of chronic kidney disease and prevent problems such as heart failure and dying of cardiovascular problems.
If you have kidney disease but are not on dialysis and do not have a transplant, then EASi-KIDNEY could be suitable for you,
BI 690517
BI 690517 is a once daily tablet recently developed to treat people with kidney disease. There is some early evidence that BI 690517 could reduce the development or worsening of kidney disease in patients with and without diabetes.
It reduces levels of the hormone aldosterone in the body, which is responsible for increasing blood pressure, potentially increasing the risk of worsening kidney disease and damaging the heart. By reducing aldosterone levels, there may be a benefit to both your heart and kidneys over the long term.
Empagliflozin
Empagliflozin is a once daily tablet recently approved to treat people with chronic kidney disease. In previous trials, empagliflozin has shown assuring evidence that it significantly reduces the risk of cardiovascular disease death and kidney disease progression in patients with and without diabetes, and is now recommended for most adults with chronic kidney disease worldwide.
Oxford University is working with doctors across the world to do a large trial to test BI 690157 in combination with empagliflozin in people with kidney disease, including people with and without diabetes. The trial results will have a major impact on how kidney disease is treated in the future, but we need volunteers to join the study and take extra tablets once a day for 3-4 years.
Where can I find out more?
- Speak to a member of the study team: Dr Streeton or Jo Mullen: Telephone number: 01275 335666
- Or review further details on our website.
What do I do if I am interested in taking part?
Please contact the study team who will be able to tell you if you are suitable for the study.
Thank you for your interest.
Providing NHS Services
Clevedon Medical Centre
Old Street
Clevedon
North Somerset
BS21 6DG
Telephone: 01275 335666
